Method and device for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement

1. A method for quantifying uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement, the method comprising:

quantifying the uptake of the at least one radiotracer in the body region of the patient of interest to the positron emission tomography measurement

by taking into account at least one permeability information item relating to permeability of at least one blood vessel of the patient determined within the scope of a dynamic contrast-enhanced magnetic resonance imaging measurement, and

by taking into account differing permeability of an used contrast agent for magnetic resonance imaging and at least one of the permeability of the at least one radiotracer and relaxivity of the contrast agent,

wherein the quantifying occurs based on data relating to the transfer of the at least one radiotracer from the at least one blood vessel of the patient into tissue surrounding the body region.

2. The method as claimed in claim 1 , wherein a standardized uptake value is determined within the scope of quantifying the uptake of the at least one radiotracer in the body region of interest.

3. The method as claimed in claim 1 , wherein at least one macromolecular substance is used as a contrast agent.

4. The method as claimed in claim 1 , wherein at least one of

magnetic resonance imaging data is recorded before, during and after the administration of a contrast agent, and

information relating to at least one native tissue signal, contrast agent enhancement in at least one blood vessel and contrast agent enhancement in at least a part of the body region of interest is determined from the recorded magnetic resonance imaging data.

5. The method as claimed in claim 1 , wherein the uptake of the at least one radiotracer in the body region of interest for the positron emission tomography measurement is quantified on the basis of at least one pharmacokinetic model.

6. The method as claimed in claim 5 , wherein, within the scope of the at least one pharmacokinetic modeling, at least one of the following is determined, allowing conclusions about at least one permeability information item:

at least one kinetic substance exchange constant,

one extracellular volume fraction, and

at least one further modeling value.

7. The method as claimed in claim 1 , wherein least one modeling value determined within the scope of pharmacokinetic modeling is displayed in at least one magnetic resonance image.

8. The method as claimed in claim 1 , wherein the at least one permeability information item is recorded simultaneously with the positron emission tomography measurement.

9. The method as claimed in claim 1 , wherein the uptake of the at least one radiotracer in the body region of interest is quantified taking into account at least one further information item.

10. The method as claimed in claim 9 , wherein the positron emission tomography measurement and at least one of the at least one permeability information item and the at least one further information item where appropriate is recorded using an integrated medical recording device.

11. The method as claimed in claim 9 , wherein the at least one of at least one permeability information item and, where appropriate, the at least one further information item is taken into account within the scope of correcting a determined uptake of the at least one radiotracer in the body region of interest.

12. The method as claimed in claim 1 , wherein the uptake of a therapeutic pharmaceutical as the at least one radiotracer is quantified.

13. The method as claimed in claim 1 , wherein the uptake of the at least one radiotracer in the body region of interest to the positron emission tomography measurement is quantified within the scope of monitoring the course of a therapy.

14. The method as claimed in claim 3 , wherein the at least one macromolecular substance includes at least one of iron oxide nanoparticles, at least one nanoscale gadolinium assembly and at least one low-molecular gadolinium complex.

15. The method as claimed in claim 2 , wherein at least one macromolecular substance is used as a contrast agent.

16. The method as claimed in claim 15 , wherein the at least one macromolecular substance includes at least one of iron oxide nanoparticles, at least one nanoscale gadolinium assembly and at least one low-molecular gadolinium complex.

17. The method as claimed in claim 5 , wherein the uptake of the at least one radiotracer in the body region of interest for the positron emission tomography measurement is quantified on the basis of the at least one pharmacokinetic model using at least one of a Brix model, a Kety model and an extended Kety model.

18. The method as claimed in claim 17 , wherein, within the scope of the at least one pharmacokinetic model, at least one of the following is determined, allowing conclusions about at least one permeability information item:

at least one kinetic substance exchange constant,

one extracellular volume fraction, and

at least one further modeling value.

19. The method as claimed in claim 9 , wherein the uptake of the at least one radiotracer in the body region of interest is quantified by at least one of

by taking into account the scattering of photons in the body region of interest,

in a detector used for the positron emission tomography measurement, and

by taking into account absorption of photons in the body region of interest.

20. A medical device, comprising:

an integrated unit configured to record positron emission tomography data and magnetic resonance imaging data for at least one radiotracer in a body region of a patient of interest; and

a computational unit configured to receive the positron emission tomography data and the magnetic resonance imaging data from the integrated unit, the computational unit being configured to quantify uptake of the at least one radiotracer in the body region of the patient of interest to a positron emission tomography measurement,

by taking into account at least one permeability information item relating to permeability of at least one blood vessel of the patient determined within the scope of a dynamic contrast-enhanced magnetic resonance imaging measurement, and

by taking into account differing permeability of an used contrast agent for magnetic resonance imaging and at least one of the permeability of the at least one radiotracer and relaxivity of the contrast agent,

wherein the quantifying occurs based on data relating to the transfer of the at least one radiotracer from the at least one blood vessel of the patient into tissue surrounding the body region.

21. A non-transitory computer readable medium configured to interact with a computer device, comprising:

program segments configured to, when executed on the computer device, quantify uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement,

by taking into account at least one permeability information item relating to permeability of at least one blood vessel of the patient determined within the scope of a dynamic contrast-enhanced magnetic resonance imaging measurement, and

by taking into account differing permeability of an used contrast agent for magnetic resonance imaging and at least one of the permeability of the at least one radiotracer and relaxivity of the contrast agent,

wherein the quantifying occurs based on data relating to the transfer of the at least one radiotracer from the at least one blood vessel of the patient into tissue surrounding the body region.